The patient was immediately given injection pheniramine and dexamethasone followed by oral prednisolone 40mg daily with levocetirizine 5 mg daily for further 5 days. The reaction subsided within 3-4 days.
FDE is a type of adverse cutaneous drug reaction which recurs at the same site on skin/mucosa each time the offending drug is administered. [1] FDEs comprise about 10% of all adverse drug reactions (ADRs), the main causative drugs being analgesics, fluoroquinolones, sulfonamides, tetracyclines, etc. [2] Common adverse cutaneous drug reactions with doxycycline are FDEs, photosensitivity, and drug reaction with eosinophilia and systemic symptoms. Doxycycline rarely may cause localized bullous FDE [3] or generalized/multifocal bullous FDE. [4] In our case, the patient experienced severe adverse cutaneous reaction impending toward Stevens-Johnson syndrome due to doxycycline on oral rechallenge test. This was very surprising to us because such type of severe reaction is usually not common in a patient with FDE after taking the culprit drug.
To conclude, during oral rechallenge in a patient with FDE, one should also be very vigilant about severe ADRs, especially if tetracycline group of medicines is the culprits for FDE. Therefore, even in the case of FDE, the patient should be closely monitored after oral rechallenge test.
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Solitary Keratoacanthoma Resolved after a Single Intralesional 5-Fluorouracil Therapy
Sir, Keratoacanthoma (KA) is a rapidly growing neoplasm of the skin with no potential for metastatic spread and may involute spontaneously in most of the cases. [1] Majority of the KA affects the sun-exposed sites in fair individuals in the age group of 40-70 years. The clinical presentation is as a solitary, pink-or flesh-colored, dome-shaped nodule with a central keratin plug and histopathological appearance aids the diagnosis. Although spontaneous regression occurs, therapy is indicated to prevent local tissue destruction and cosmetic purpose. We present a 63-year-old male with solitary KA on the dorsum of the left hand, which completely resolved with a single dose of 0.5 ml intralesional 5-fluorouracil (5-FU).
A 63-year-old fair skin male presented with solitary, dome-shaped, asymptomatic lesion over the dorsum of the left hand. The lesion had grown to the present size over a period of 2 months. The patient denied any history of trauma or any previous skin lesion on the affected area.
The cutaneous examination revealed a solitary, well-circumscribed, firm, skin-colored to erythematous dome-shaped nodule measuring 3 cm × 3 cm, over the dorsum of the left hand [ Figure 1 ]. Its surface was smooth, shiny, and showed crateriform central area with keratin plug. The lesion was slightly mobile and not attached to the underlying structure. No regional adenopathy noted, and the patient was otherwise healthy.
Skin biopsy showed pseudoepitheliomatous hyperplasia which did not extend below the level of the sweat glands, large cup-like crater filled with keratin with adjacent epidermis extending such as a buttress, multiple keratin pearls, and eosinophilic glassy keratinocytes around keratin pearls showing the shell of proliferations at center [ Figure 2 ]. There were no atypical keratinocytes or abnormal mitotic figures. On the basis of clinical presentation and histopathological findings, we diagnosed a case of KA.
We injected 0.5 ml of 5-FU (50 mg/ml) into the lesion, circumferentially at three to four sites and at the base. The patient was followed weekly; within 2 weeks of therapy, the tumor size was reduced by 50% [ Figure 3 ]. Within the next 7 days, the lesion had almost completely resolved with residual slight hyperpigmentation [ Figure 4 ].
KA is a benign tumor derived from a hair follicle and is more common in males over sun-damaged skin of face, dorsum of hand and forearm. It was first described by Sir Jonathan Hutchinson in the year 1888. [2] KA usually arises de novo but has been reported in association with inflammatory dermatosis, congenital skin lesions, and scars.
The clinical appearance may be confused with that of squamous cell carcinoma, molluscum contagiosum, or sebaceous carcinoma.
Histologically, KA is characterized by central-keratin filled depression surrounded by pseudoepitheliomatous hyperplasia. The epidermal strands show few atypical cells with nuclear atypia, atypical mitoses, and dyskeratotic cells. [3] Solitary KA is usually treated by surgical excision. Other treatment modalities include electrosurgery, cryotherapy, radiotherapy, systemic chemotherapy, and topical cytotoxic agent. Intralesional 5-FU is found to be safe, effective, inexpensive treatment with excellent patient acceptance, ease of administration, and good cosmetic results. [3] [4] [5] It has shown to produce an accelerated regression of KA. Mild pain or irritation may be expected at the site of injection. It interferes with DNA synthesis resulting in unbalanced cell growth and death of cells that are proliferating more rapidly. It is ideal for patients with multiple lesions of KA or surgically contraindicated patients.
In prior studies, [3] [4] [5] [6] the investigators did not perform pre-injection histopathology of lesions in all cases, and also lesions had cleared after multiple weekly intralesional 5-FU sessions (minimum 2-3 weekly sessions). They injected single KA lesion at multiple sites circumferentially. Allergic reactions from 5-FU as described by Goette and Odom [6] were not observed in our patient. This is the first-ever case of KA from Indian population which completely regressed after single intralesional 5 FU (0.5 ml) session and without circumferential multiple site injections.
There was no recurrence of lesion after 12 months of follow-up; hence, besides its high efficacy and no recurrence, 5-FU therapy has good cosmetic results, excellent patient acceptance, and low cost which is undoubtedly important in developing countries. However, this is a single-case study; hence, multiple such studies are required to validate the result.
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